Skip to content

Seagen’s New CEO Epstein Hunts for Cancer Deals

David Epstein

David Epstein

Photographer: Gianluca Colla/Bloomberg

Seagen Inc.’s new Chief Executive Officer David Epstein said he’s hunting for deals for emerging oncology drugs while keeping internal focus on the drugmaker’s core technology for attacking tumors. 

The company plans to pursue licensing, partnerships or asset acquisitions with biotech startups, Epstein said Tuesday in an interview at the JPMorgan Healthcare Conference in San Francisco. The recent downturn in biotech stocks is pressuring industry companies to find cash, which could open up more opportunity for Seagen to strike deals, he said.